Alizarin represented a promising approach to inhibit cell proliferation of breast cancer by modulating estrogen receptor mediated effects on MDM2/p-Rb/E2F1 axis concomitantly with activating apoptosis of cancer cells. Here, RB1 is linked to cancer.